{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:09Z","timestamp":1787387049270,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03626-z","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:34:25Z","timestamp":1780302865000},"page":"3929-3944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration\u2011Sensitive Prostate Cancer"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J.","family":"Freedland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9819-8737","authenticated-orcid":false,"given":"Amanda","family":"Ribbands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0169-1443","authenticated-orcid":false,"given":"Jake","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9521-797X","authenticated-orcid":false,"given":"Tom","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Bland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eblys","family":"Touya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina I.","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"2","key":"3626_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27(2):192\u2013201. https:\/\/doi.org\/10.1038\/s41391-023-00712-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3626_CR2","unstructured":"Cornford P, Tilki D, van den Bergh RCN, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy.pdf (2024). Accessed July 15 2025."},{"issue":"16","key":"3626_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"},{"issue":"20","key":"3626_CR4","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/JCO.23.00155","volume":"41","author":"KS Virgo","year":"2023","unstructured":"Virgo KS, Rumble RB, Talcott J. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2023;41(20):3652\u20136. https:\/\/doi.org\/10.1200\/JCO.23.00155.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3626_CR5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209(6):1082\u201390. https:\/\/doi.org\/10.1097\/JU.0000000000003452.","journal-title":"J Urol"},{"key":"3626_CR6","unstructured":"US Food & Drug Administration. FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enzalutamide-non-metastatic-castration-sensitive-prostate-cancer-biochemical-recurrence (2023). Accessed June 11, 2025."},{"key":"3626_CR7","unstructured":"Astellas Pharma US Inc. Full prescribing information: XTANDI\u00ae (enzalutamide) for oral use. https:\/\/www.astellas.us\/docs\/us\/12A005-ENZ-WPI.pdf (2023). Accessed Jan 21, 2025."},{"key":"3626_CR8","unstructured":"European Medicines Agency. Xtandi. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xtandi (2024). Accessed Nov 11, 2024."},{"key":"3626_CR9","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V2.2026. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V2.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 23, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"6","key":"3626_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","volume":"17","author":"GM Duchesne","year":"2016","unstructured":"Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase\u00a03 trial. Lancet Oncol. 2016;17(6):727\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(16)00107-8.","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"3626_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.5018","volume":"36","author":"A Loblaw","year":"2018","unstructured":"Loblaw A, Bassett J, D\u2019Este C, et al. Timing of androgen deprivation therapy for prostate cancer patients after radiation: planned combined analysis of two randomized phase\u00a03 trials. J Clin Oncol. 2018;36(15_suppl):5018. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.5018.","journal-title":"J Clin Oncol"},{"issue":"33","key":"3626_CR12","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1200\/jco.24.01134","volume":"42","author":"B Tombal","year":"2024","unstructured":"Tombal B, Giannarini G. Systemic treatment for biochemical recurrence of localized prostate cancer: do not EMBARK on when, if the answer is how. J Clin Oncol. 2024;42(33):3996\u20137. https:\/\/doi.org\/10.1200\/jco.24.01134.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3626_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa2510310","volume":"394","author":"ND Shore","year":"2025","unstructured":"Shore ND, de Almeida LM, De Giorgi U, et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2026;394(6):563\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2510310.","journal-title":"N Engl J Med"},{"issue":"2","key":"3626_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/upj.0000000000000189","volume":"8","author":"A Moradzadeh","year":"2021","unstructured":"Moradzadeh A, Howard LE, Freedland SJ, et al. The impact of comorbidity and age on timing of androgen deprivation therapy in men with biochemical recurrence after radical prostatectomy. Urol Pract. 2021;8(2):238\u201345. https:\/\/doi.org\/10.1097\/upj.0000000000000189.","journal-title":"Urol Pract"},{"issue":"3","key":"3626_CR15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41391-024-00894-0","volume":"28","author":"SJ Freedland","year":"2025","unstructured":"Freedland SJ, Gao W, Lax A, et al. Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment. Prostate Cancer Prostatic Dis. 2025;28(3):809\u201316. https:\/\/doi.org\/10.1038\/s41391-024-00894-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"17","key":"3626_CR16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591\u20137. https:\/\/doi.org\/10.1001\/jama.281.17.1591.","journal-title":"JAMA"},{"issue":"22","key":"3626_CR17","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326\u201347. https:\/\/doi.org\/10.1200\/JCO.2018.78.8687.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3626_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.48707","volume":"7","author":"N Agarwal","year":"2024","unstructured":"Agarwal N, George DJ, Klaassen Z, et al. Physician reasons for or against treatment intensification in patients with metastatic prostate cancer. JAMA Netw Open. 2024;7(12):e2448707. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.48707.","journal-title":"JAMA Netw Open"},{"issue":"suppl 4","key":"3626_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003518","volume":"209","author":"ND Shore","year":"2023","unstructured":"Shore ND, de Almeida LM, De Giorgi U, et al. LBA02-09 EMBARK: A phase\u00a03 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. J Urol. 2023;209(suppl 4):e1190. https:\/\/doi.org\/10.1097\/JU.0000000000003518.","journal-title":"J Urol"},{"issue":"2","key":"3626_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41391-023-00711-0","volume":"27","author":"JW Moul","year":"2024","unstructured":"Moul JW, Shore ND, Pienta KJ, Czernin J, King MT, Freedland SJ. Application of next-generation imaging in biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2024;27(2):202\u201311. https:\/\/doi.org\/10.1038\/s41391-023-00711-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"3626_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.52971","volume":"8","author":"A Holzgreve","year":"2025","unstructured":"Holzgreve A, Armstrong WR, Clark KJ, et al. PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw Open. 2025;8(1):e2452971. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.52971.","journal-title":"JAMA Netw Open"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03626-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03626-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03626-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:50Z","timestamp":1787385890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03626-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3626"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03626-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version has been revised due to update in article text.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephen J. Freedland: consulting or advisory role with Astellas Pharma Inc., AstraZeneca, Bayer, Eli Lilly, Exact Sciences, Johnson & Johnson Innovative Medicine (formerly Janssen), Merck, Novartis, Pfizer Inc., Sanofi, and Sumitomo Pharma America, Inc. (formerly Myovant Sciences). Amanda Ribbands, Jake Butcher, Tom Brown: employees of Adelphi Real World. Ma\u00eblys Touya: employee and shareholder of Astellas Pharma Inc. David Russell, Jasmina I. Ivanova: employees and shareholders of Pfizer Inc. Christopher S. Bland: former employee of Pfizer Inc. Current affiliation: Ipsen Pharma, Cambridge, MA, USA.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Pearl International Review Board provided exemption for the ARW independent retrospective nmCSPC survey (reference number 2023-0099). Consent was provided by the physicians via a check box, which they ticked, acknowledging their participation in the survey. All participants were informed of how their data would be used and that they had the right to withdraw at any time. Participants were also informed that the results from the survey may be used for publication in scientific journals. No additional consent or approval was required due to the secondary nature of the data analyzed. All data were fully de-identified and aggregated before receipt and analysis by ARW. Data collection was conducted in full accordance with the European Pharmaceutical Market Research Association guidelines and the US Health Insurance Portability and Accountability Act 1996, as well as the Health Information Technology for Economic and Clinical Health Act legislation.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}